673 related articles for article (PubMed ID: 17371720)
21. 3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis.
Zhang XM; Yu D; Zhang HL; Dai Y; Bi D; Liu Z; Prince MR; Li C
J Magn Reson Imaging; 2008 Jun; 27(6):1309-16. PubMed ID: 18504761
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin.
Dafni H; Israely T; Bhujwalla ZM; Benjamin LE; Neeman M
Cancer Res; 2002 Nov; 62(22):6731-9. PubMed ID: 12438274
[TBL] [Abstract][Full Text] [Related]
23. Peripheral washout phenomenon in an animal tumour model: comparison of dynamic magnetic resonance imaging using a small molecular contrast medium with histology.
Drees R; Hünigen H; Wagner S; Schnorr J; Plendl J; Taupitz M
Vet Comp Oncol; 2008 Sep; 6(3):151-61. PubMed ID: 19178675
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
25. Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice.
de Lussanet QG; Beets-Tan RG; Backes WH; van der Schaft DW; van Engelshoven JM; Mayo KH; Griffioen AW
Eur J Cancer; 2004 May; 40(8):1262-8. PubMed ID: 15110892
[TBL] [Abstract][Full Text] [Related]
26. In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts.
Huuse EM; Moestue SA; Lindholm EM; Bathen TF; Nalwoga H; Krüger K; Bofin A; Maelandsmo GM; Akslen LA; Engebraaten O; Gribbestad IS
J Magn Reson Imaging; 2012 May; 35(5):1098-107. PubMed ID: 22170753
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
28. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.
Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Horsman MR
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):859-66. PubMed ID: 18164835
[TBL] [Abstract][Full Text] [Related]
29. Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI.
Su MY; Baik HM; Yu HJ; Chen JH; Mehta RS; Nalcioglu O
Technol Cancer Res Treat; 2006 Aug; 5(4):401-10. PubMed ID: 16866570
[TBL] [Abstract][Full Text] [Related]
30. Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS.
Jensen LR; Huuse EM; Bathen TF; Goa PE; Bofin AM; Pedersen TB; Lundgren S; Gribbestad IS
NMR Biomed; 2010 Jan; 23(1):56-65. PubMed ID: 19650073
[TBL] [Abstract][Full Text] [Related]
31. Comparison of tumor histology to dynamic contrast enhanced magnetic resonance imaging-based physiological estimates.
Aref M; Chaudhari AR; Bailey KL; Aref S; Wiener EC
Magn Reson Imaging; 2008 Nov; 26(9):1279-93. PubMed ID: 18487033
[TBL] [Abstract][Full Text] [Related]
32. Assessment of hypoxia in human cervical carcinoma xenografts by dynamic contrast-enhanced magnetic resonance imaging.
Ellingsen C; Egeland TA; Gulliksrud K; Gaustad JV; Mathiesen B; Rofstad EK
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):838-45. PubMed ID: 19215820
[TBL] [Abstract][Full Text] [Related]
33. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
[TBL] [Abstract][Full Text] [Related]
34. Parametric imaging of tumor perfusion using flow- and permeability-limited tracers.
Bogin L; Margalit R; Mispelter J; Degani H
J Magn Reson Imaging; 2002 Sep; 16(3):289-99. PubMed ID: 12205585
[TBL] [Abstract][Full Text] [Related]
35. Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study.
Chou CP; Wu MT; Chang HT; Lo YS; Pan HB; Degani H; Furman-Haran E
Acad Radiol; 2007 May; 14(5):561-73. PubMed ID: 17434070
[TBL] [Abstract][Full Text] [Related]
36. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
[TBL] [Abstract][Full Text] [Related]
37. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Moasser MM; Wilmes LJ; Wong CH; Aliu S; Li KL; Wang D; Hom YK; Hann B; Hylton NM
J Magn Reson Imaging; 2007 Dec; 26(6):1618-25. PubMed ID: 17968965
[TBL] [Abstract][Full Text] [Related]
38. Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation.
Dafni H; Kim SJ; Bankson JA; Sankaranarayanapillai M; Ronen SM
Magn Reson Med; 2008 Oct; 60(4):822-33. PubMed ID: 18816866
[TBL] [Abstract][Full Text] [Related]
39. A method for pharmacokinetic modelling of dynamic contrast enhanced MRI studies of rapidly enhancing lesions acquired in a clinical setting.
Radjenovic A; Ridgway JP; Smith MA
Phys Med Biol; 2006 May; 51(9):N187-97. PubMed ID: 16625029
[TBL] [Abstract][Full Text] [Related]
40. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.
Choyke PL; Dwyer AJ; Knopp MV
J Magn Reson Imaging; 2003 May; 17(5):509-20. PubMed ID: 12720260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
